Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Early Phase 1
2(66.7%)
Phase 2
1(33.3%)
3Total
Early Phase 1(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06645808Early Phase 1Recruiting

PET-imaging of Two Vartumabs in Patients With Solid Tumors

Role: collaborator

NCT06204237Early Phase 1Recruiting

Safety, Tolerability, and Biodistribution of [89Zr]Zr-DFO-APAC in Subjects With PAOD/CLI and Healthy Volunteers (Acronyms: 89Zr = Zirconium-89, DFO = Desferrioxamine, APAC = AntiPlatelet AntiCoagulant, PET/CT = Positron Emission Tomography/Computed Tomography)

Role: collaborator

NCT05124483Phase 2Unknown

Anti-COVID19 VaccinaTion AKS-452 BOOSTER (ACT-BOOSTER Study)

Role: collaborator

All 3 trials loaded